Gilead Sciences (NASDAQ:GILD) has agreed to collaborate with Cartography Biosciences to develop new therapies for triple-negative breast cancer and adenocarcinoma, the most common form of non-small cell lung cancer.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,